Publications by authors named "M Coskunturk"
Article Synopsis
- This study investigates the effectiveness and safety of a combination therapy using immune checkpoint inhibitors (ICIs) for certain subgroups of metastatic castration-resistant prostate cancer (mCRPC) patients who show an immunogenic profile.
- The trial involved 69 patients with specific genetic markers and assessed the disease control rate after treatment, aiming to exceed 22%.
- Results showed that 38% of patients achieved disease control beyond 6 months, with the highest success in patients with mismatch repair deficiency, but treatment led to significant side effects in some cases, with 20% permanently discontinuing therapy.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are effective for some metastatic urothelial cancer (mUC) patients, but only 20-25% see a durable response.
- A study investigated the potential of measuring circulating tumor DNA (ctDNA) levels during treatment to predict responsiveness to ICIs in mUC patients, using a discovery cohort of 40 and a validation cohort of 16.
- Results showed that increases in ctDNA at 3 and 6 weeks were strongly associated with shorter progression-free survival and overall survival, indicating that early ctDNA changes could guide better management of treatment strategies.
Ecthymagangrenosum is a painful node that rapidly progresses to a necrotic ulcer and occurs as a result of a local infection or hematogenous spread. It has a high mortality rate when treatment is delayed. We describe a 19-year-old male with neutropenic fever due to ecthymagangrenosum caused by Pseudomonas aeruginosa without bacteremia.
View Article and Find Full Text PDFA 25-year-old man was treated with pembrolizumab for a relapsed-refractory primary mediastinal large B-cell lymphoma. On an evaluation PET-CT scan multiple 'reversed halo signs' were noticed. No infectious cause was established and we diagnosed the lesions as pembrolizumab-induced pneumonitis, an immune-related adverse event.
View Article and Find Full Text PDFBackground: In the past years, interest in patient treatment preferences is growing. Our objectives were: (1) to assess and compare the minimal required benefit for patients with cancer, patients without cancer and healthcare professionals to make chemotherapy acceptable and (2) to obtain insight into attitudes towards societal costs of cancer treatment.
Patients And Methods: We performed a prospective survey consisting of hypothetical scenarios among patients with cancer, patients without cancer and healthcare professionals.